← Back to patent-cliff list
瑞派替尼
Tier C — Watch / tradeRipretinib · all drugs expiring in 2032 →
Deciphera Pharmaceuticals Llc
Originator
2020
First approval
2032
Expiry (public)
$0.3B *
Peak sales
化学药
Type
Targets：KIT、PDGFR-α、PDGFR-β、TIE2、VEGFR2、B-raf
Brand：Qinlock、擎乐
Indications (approved)：胃肠道间质瘤
Regional status
US
批准上市
2020-05-15
EU
批准上市
2021-11-18
China
批准上市
2021-03-30
Japan
申请上市
2026-03-26
Synthetic routes & intermediates5 routes
Originator routes × 0Optimised (non-patent) × 5Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OptimisedRoute 1Steps 7 · Total yield 0.047 g
| Code | CAS No. | Intermediate |
|---|---|---|
| DCC-2618 | - | N-(2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide hydrochloride |
| DCC-2618-001 | 17368-12-6 | 2-chloropyridin-4-ol |
| DCC-2618-002 | 2105-61-5 | 1,2,4-trifluoro-5-nitrobenzene |
| DCC-2618-003 | 1225278-64-7 | 2-chloro-4-(2,5-difluoro-4-nitrophenoxy)pyridine |
| DCC-2618-004 | 1225278-65-8 | 4-((2-chloropyridin-4-yl)oxy)-2,5-difluoroaniline |
| DCC-2618-005 | 761446-44-0Available | 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole |
| DCC-2618-006 | 1225278-35-2 | 2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)aniline |
| DCC-2618-007 | 113020-21-6 | 1-(methoxycarbonyl)cyclopropane-1-carboxylic acid |
| DCC-2618-008 | 1225278-79-4 | methyl 1-((2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate |
| DCC-2618-009 | 1225278-49-8 | lithium 1-((2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)carbamoyl)cyclopropane-1-carboxylate |
| DCC-2618-010 | 1225278-16-9 | N-(2,5-difluoro-4-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide |
OptimisedRoute 2Steps 8 · Total yield /
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)819703-1-a | 105-50-0 | 1,3-Acetonedicarboxylic acid diethyl ester |
| (II)819703-1-a | 6975-44-6 | 4,6-Dihydroxynicotinic acid ethyl ester |
| (III)819703-1-a | 40296-46-6 | 2,4-Dichloro-5-carbethoxypyridine |
| (IV)819703-1-a | 75-04-7 | Aminoethane |
| (V)819703-1-a | 959162-97-1 | 6-Chloro-4-ethylamino-nicotinic acid ethyl ester |
| (VI)819703-1-a | 959162-99-3 | [6-Chloro-4-(ethylamino)pyridin-3-yl]methanol |
| (VII)819703-1-a | 959163-01-0 | 6-Chloro-4-(ethylamino)nicotinaldehyde |
| (VIII)819703-1-a,(VIII)819703-1-b | 1442471-26-2 | Ethyl (5-amino-2-bromo-4-fluorophenyl)acetate |
| (IX)819703-1-a | 1442470-52-1 | 3-(5-Amino-2-bromo-4-fluorophenyl)-7-chloro-1-ethyl-1,6-naphthyridin-2(1H)-one |
| (X)819703-1-a | 74-89-5 | Aminomethane |
| (XIa)819703-1-a | 1442470-53-2 | 3-(5-Amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one |
| (XIb)819703-1-a | - | 3-(5-Amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one hydrochloride |
| (XIIa)819703-1-a | 103-71-9 | 4-Isocyanatobenzene |
| (XIIb)819703-1-a | 4930-03-4 | Carbanilic acid phenyl ester |
| (XIII)819703-1-a | 61150-59-2 | 2-(2-Bromo-4-fluorophenyl)acetic acid |
| (XIV)819703-1-a | 1012879-09-2 | (2-Bromo-4-fluoro-5-nitrophenyl)acetic acid |
| (XV)819703-1-a | 1012879-10-5 | Ethyl (2-bromo-4-fluoro-5-nitrophenyl)acetate |
OptimisedRoute 3Steps 3 · Total yield /
| Code | CAS No. | Intermediate |
|---|---|---|
| (VIII)819703-1-a,(VIII)819703-1-b | 1442471-26-2 | Ethyl (5-amino-2-bromo-4-fluorophenyl)acetate |
| (XIb)819703-1-a | - | 3-(5-Amino-2-bromo-4-fluorophenyl)-1-ethyl-7-(methylamino)-1,6-naphthyridin-2(1H)-one hydrochloride |
| (XIIb)819703-1-a | 4930-03-4 | Carbanilic acid phenyl ester |
| (XVI)819703-1-b | 192508-36-4 | (4-Fluoro-3-nitrophenyl)acetic acid |
| (XVII)819703-1-b | 858972-16-4 | Ethyl (4-fluoro-3-nitrophenyl)acetate |
| (XVIII)819703-1-b | 858972-17-5 | Ethyl (3-amino-4-fluorophenyl)acetate |
OptimisedRoute 4Steps 5 · Total yield /
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)819703-2-a | 1807256-54-7 | Methyl (2-bromo-4-fluoro-5-nitrophenyl)acetate |
| (II)819703-2-a | 1060809-78-0 | 6-Chloro-4-nitropyridine-3-carbaldehyde |
| (III)819703-2-a | - | Methyl (2Z)-2-(2-bromo-4-fluoro-5-nitrophenyl)-3-(6-chloro-4-nitropyridin-3-yl)prop-2-enoate |
| (IV)819703-2-a | 2766184-37-4 | 3-(5-Amino-2-bromo-4-fluorophenyl)-7-chloro-1,6-naphthyridin-2(1H)-one |
| (V)819703-2-a | 62-53-3 | Aminobenzene |
| (VI)819703-2-a | 32315-10-9 | 1,1,1-Trichloromethanol 1,1'-carbonate |
| (VII)819703-2-a | 2766184-38-5 | N-[4-Bromo-5-(7-chloro-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl]-N'-phenylurea |
| (VIII)819703-2-a | 75-03-6Available | 1-Iodoethane |
| (IX)819703-2-a | 1442474-38-5 | N-[4-Bromo-5-(7-chloro-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl]-N'-phenylurea |
| (X)819703-2-a | 74-89-5 | Aminomethane |
OptimisedRoute 5Steps 3 · Total yield /
| Code | CAS No. | Intermediate |
|---|---|---|
| (I)819703-3-a | 1012879-09-2 | (2-Bromo-4-fluoro-5-nitrophenyl)acetic acid |
| (II)819703-3-a | 4930-03-4 | Carbanilic acid phenyl ester |
| (III)819703-3-a | - | Ethyl [2-bromo-4-fluoro-5-[(phenylcarbamoyl)amino]phenyl]acetate |
| (IV)819703-3-a | 959163-01-0 | 6-Chloro-4-(ethylamino)nicotinaldehyde |
| (V)819703-3-a | 1442474-38-5 | N-[4-Bromo-5-(7-chloro-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl]-N'-phenylurea |
| (VI)819703-3-a | 74-89-5 | Aminomethane |
Frequently asked questions
What are the approved indications of Ripretinib?
Approved indications include: 胃肠道间质瘤.
When does the Ripretinib patent expire?
Based on public sources, the Ripretinib patent expires in 2032.
How many synthesis routes are recorded for Ripretinib?
5 synthesis routes are recorded; the shortest is 3 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Ripretinib intermediates?
2 intermediate CAS of Ripretinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Ripretinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24